PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $96,556 | +1313.7% | 9,311 | +1852.0% | 0.00% | – |
| Q2 2023 | $6,830 | +56816.7% | 477 | -72.0% | 0.00% | – |
| Q1 2023 | $12 | +140.0% | 1,705 | +250.8% | 0.00% | – |
| Q4 2022 | $5 | -100.0% | 486 | -89.1% | 0.00% | -100.0% |
| Q3 2022 | $49,000 | +8.9% | 4,451 | -17.3% | 0.00% | 0.0% |
| Q2 2022 | $45,000 | -11.8% | 5,380 | +45.6% | 0.00% | – |
| Q1 2022 | $51,000 | +537.5% | 3,696 | +788.5% | 0.00% | – |
| Q4 2021 | $8,000 | -57.9% | 416 | -31.4% | 0.00% | – |
| Q3 2021 | $19,000 | -85.4% | 606 | -84.2% | 0.00% | -100.0% |
| Q2 2021 | $130,000 | +165.3% | 3,833 | +191.3% | 0.00% | +200.0% |
| Q1 2021 | $49,000 | -31.9% | 1,316 | -39.0% | 0.00% | -50.0% |
| Q4 2020 | $72,000 | -82.5% | 2,157 | -80.8% | 0.00% | -60.0% |
| Q3 2020 | $411,000 | +478.9% | 11,212 | +420.5% | 0.01% | +66.7% |
| Q2 2020 | $71,000 | – | 2,154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
| Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
| Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
| 683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
| Western Standard LLC | 109,055 | $920,000 | 0.70% |
| MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
| Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
| StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
| Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |